SCHEMBL30734233

SCHEMBL30734233

Nc1cc(-c2ccc3ncnc(N4CCN(c5ccc(F)cc5)CC4)c3c2)ccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.55
BACE1 P56817 1/20 0.55
CYP1A2 P05177 10/20 0.49
CYP3A4 P08684 10/20 0.49
ALDH1A1 P00352 9/20 0.49
CLK4 Q9HAZ1 8/20 0.49
LMNA P02545 7/20 0.49
HIF1A Q16665 7/20 0.49
MAPK1 P28482 5/20 0.49
MAPT P10636 4/20 0.49
HTT P42858 1/20 0.49
MAPKAPK2 P49137 1/20 0.48
CYP2D6 P10635 7/20 0.48
USP2 O75604 6/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
MAP4K4 O95819 1/20 0.48
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.46
CYP2C19 P33261 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30734232 0.89 ALDH1A1 (0.49) ACHEBACE1CYP1A2CYP3A4ALDH1A1
SCHEMBL30734187 0.89 ACHE (0.53) ACHEBACE1CYP1A2CYP3A4ALDH1A1
SCHEMBL30734231 0.89 CYP3A4 (0.52) CYP1A2CYP3A4ALDH1A1CLK4LMNA
SCHEMBL30734134 0.86 ACHE (0.58) ACHEBACE1CYP1A2CYP3A4ALDH1A1
SCHEMBL30734212 0.86 HTT (0.49) CYP1A2CYP3A4ALDH1A1CLK4LMNA
SCHEMBL30734241 0.84 MAPKAPK2 (0.53) ALDH1A1LMNAMAPK1MAPTHTT
SCHEMBL31745229 0.83 CYP1A2 (0.52) CYP1A2CYP3A4ALDH1A1CLK4LMNA
SCHEMBL4358134 0.83 ACHE (0.61) ACHEBACE1CYP1A2CYP3A4ALDH1A1
SCHEMBL30734169 0.83 CYP3A4 (0.54) CYP1A2CYP3A4ALDH1A1CLK4LMNA
SCHEMBL30734221 0.83 LMNA (0.51) CYP1A2CYP3A4ALDH1A1CLK4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF UNIV ARIZONA (US) 2025-12-18 US disclosed
EP-4543888-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF Arizona Board of Regents on behalf of The University of Arizona (US) 2025-04-30 EP disclosed
WO-2023250083-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK3, CLK1 ACHE 3704/4885BACE1 1412/4885CYP1A2 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.